Acadia Healthcare Company Inc (ACHC)
Return on equity (ROE)
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (ttm) | US$ in thousands | 255,612 | 280,726 | -5,116 | -11,299 | -21,667 | -18,272 | 270,537 | 278,317 | 273,139 | 282,293 | 277,320 | 241,755 | 190,635 | -663,315 | -692,443 | -695,878 | -672,132 | 100,286 | 105,854 | 112,915 |
| Total stockholders’ equity | US$ in thousands | 3,073,720 | 3,031,520 | 2,952,720 | 2,866,020 | 2,781,970 | 2,712,560 | 2,921,020 | 2,839,600 | 2,812,730 | 2,743,710 | 2,663,040 | 2,574,510 | 2,517,490 | 2,434,450 | 2,356,590 | 2,298,000 | 1,899,460 | 2,606,640 | 2,503,340 | 2,464,170 |
| ROE | 8.32% | 9.26% | -0.17% | -0.39% | -0.78% | -0.67% | 9.26% | 9.80% | 9.71% | 10.29% | 10.41% | 9.39% | 7.57% | -27.25% | -29.38% | -30.28% | -35.39% | 3.85% | 4.23% | 4.58% |
December 31, 2024 calculation
ROE = Net income (ttm) ÷ Total stockholders’ equity
= $255,612K ÷ $3,073,720K
= 8.32%
Acadia Healthcare Company Inc's return on equity (ROE) has shown a mixed performance over the last few years. The ROE stood at relatively low levels in the first half of 2020, ranging from 3.85% to 4.58%. However, there was a significant decline in the ROE by the end of 2020 and through the first three quarters of 2021, with negative ROE figures indicating a decrease in profitability relative to shareholder equity.
From December 2021 onwards, Acadia Healthcare's ROE started to improve, reaching positive levels by March 2022 and gradually increasing to around 10% by June 2022. The ROE remained relatively stable throughout 2023, hovering around 9-10%. There was a slight decline in the ROE in the third and fourth quarters of 2023, with negative figures recorded again.
By the end of 2024, the ROE recovered to positive territory, with an ROE of 8.32% in December 2024. Overall, although the company experienced periods of negative ROE, there was a general improvement in profitability and efficiency in generating returns for shareholders towards the end of the period under review.
Peer comparison
Dec 31, 2024